Published in Cancer Growth Metastasis on July 23, 2015
Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma. Oncotarget (2016) 0.81
Prediction of miRNA-disease associations with a vector space model. Sci Rep (2016) 0.79
Hybrid Cells Derived from Human Breast Cancer Cells and Human Breast Epithelial Cells Exhibit Differential TLR4 and TLR9 Signaling. Int J Mol Sci (2016) 0.76
High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients. Virchows Arch (2017) 0.76
A Transcriptional Regulatory Role for the Membrane Type-1 Matrix Metalloproteinase in Carcinogen-Induced Inflammasome Gene Expression. Gene Regul Syst Bio (2017) 0.75
Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy. Front Oncol (2017) 0.75
Solid-in-oil nanodispersions for transdermal drug delivery systems. Biotechnol J (2016) 0.75
Regulatory T Cell and Forkhead Box Protein 3 as Modulators of Immune Homeostasis. Front Immunol (2017) 0.75
Pathogen recognition and innate immunity. Cell (2006) 44.14
Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature (2006) 24.43
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
Pattern recognition receptors and inflammation. Cell (2010) 21.05
Cryopyrin activates the inflammasome in response to toxins and ATP. Nature (2006) 18.74
Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature (2004) 14.80
Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol (2009) 14.33
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
The inflammasomes: guardians of the body. Annu Rev Immunol (2009) 12.89
Toll-like receptors in innate immunity. Int Immunol (2005) 12.24
The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol (2008) 10.39
Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem (2003) 8.34
The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol (2009) 7.80
Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol (2007) 7.23
Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med (2007) 6.52
Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem (2002) 6.16
Toll-like receptor signaling pathways. Science (2003) 5.86
Pathogen recognition by the innate immune system. Int Rev Immunol (2011) 5.76
Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol (2001) 5.27
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98
Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med (2003) 4.96
HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock (2006) 4.53
Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell (2008) 4.43
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov (2012) 4.40
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol (2009) 3.85
Inflammasomes: guardians of cytosolic sanctity. Immunol Rev (2009) 3.58
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res (2006) 3.21
Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet (2008) 3.11
A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood (2007) 3.09
The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol (2009) 3.01
Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91
Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest (2008) 2.88
Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol (2010) 2.85
Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet (2008) 2.67
TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science (2012) 2.66
The role of beta7 integrins in CD8 T cell trafficking during an antiviral immune response. J Exp Med (1999) 2.62
TLR signaling by tumor and immune cells: a double-edged sword. Oncogene (2008) 2.18
Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis (2007) 2.18
Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem (2009) 2.12
Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med (2006) 1.98
IL-10-dependent partial refractoriness to Toll-like receptor stimulation modulates gut mucosal dendritic cell function. Eur J Immunol (2008) 1.97
Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev (2010) 1.96
Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol (2009) 1.90
Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol (2006) 1.88
IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci U S A (2000) 1.86
MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med (2012) 1.82
Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J Exp Med (2013) 1.77
Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res (2001) 1.70
Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? Cell Div (2010) 1.70
A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol (2005) 1.70
Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res (2006) 1.69
NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol (2011) 1.69
Role of Toll-like receptors in gastrointestinal malignancies. Oncogene (2008) 1.69
Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat Med (2012) 1.68
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol (2009) 1.66
RNA recognition by human TLR8 can lead to autoimmune inflammation. J Exp Med (2013) 1.64
Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother (2010) 1.60
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron (2009) 1.60
TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol (2005) 1.48
Role of adapters in Toll-like receptor signalling. Biochem Soc Trans (2003) 1.47
Decorin: a guardian from the matrix. Am J Pathol (2012) 1.46
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest (2012) 1.45
TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene (2008) 1.41
Identification of a TLR4- and TRIF-dependent activation program of dendritic cells. Eur J Immunol (2004) 1.39
Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol (2002) 1.39
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol (2009) 1.39
The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep (2011) 1.39
Succinate: a metabolic signal in inflammation. Trends Cell Biol (2013) 1.34
Complexity of danger: the diverse nature of damage-associated molecular patterns. J Biol Chem (2014) 1.32
Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APCMin/+ mice. Carcinogenesis (2012) 1.31
Endotoxin/lipopolysaccharide activates NF-kappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J Immunol (2003) 1.31
The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal (2009) 1.28
Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis (2010) 1.28
Helicobacter pylori infection enhances mucosal interleukin-1 beta, interleukin-6, and the soluble receptor of interleukin-2. Int J Clin Lab Res (1996) 1.28
Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer (2008) 1.25
STAT3 can serve as a hit in the process of malignant transformation of primary cells. Cell Death Differ (2012) 1.24
The Yin and Yang of Toll-like receptors in cancer. Oncogene (2013) 1.23
ATP release and purinergic signaling in NLRP3 inflammasome activation. Front Immunol (2013) 1.23
Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. Part Fibre Toxicol (2013) 1.16
Extravasation of leukocytes in comparison to tumor cells. Cell Commun Signal (2008) 1.16
Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer. Mol Cancer Ther (2013) 1.15
Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother (2010) 1.14
Sterile inflammatory responses mediated by the NLRP3 inflammasome. Eur J Immunol (2010) 1.14
Expression of chemokines and chemokine receptors in human colon cancer. Methods Enzymol (2009) 1.14
TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology (2002) 1.14
IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Mol Cancer (2012) 1.12
Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res (2011) 1.11
Expression of CXCR4 and its ligand SDF-1 in intestinal-type gastric cancer is associated with lymph node and liver metastasis. Anticancer Res (2009) 1.11
Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection. Proc Natl Acad Sci U S A (2014) 1.11
Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol (2011) 1.10
Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation. Front Immunol (2014) 1.10
Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system. Br J Cancer (2009) 1.10
Up-regulation of pro-inflammatory genes as adaptation to hypoxia in MCF-7 cells and in human mammary invasive carcinoma microenvironment. Cancer Sci (2010) 1.10
Targeting TLR/IL-1R signalling in human diseases. Mediators Inflamm (2010) 1.09
Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity. Clin Cancer Res (2012) 1.09
TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol (2009) 1.08
A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis. Nat Cell Biol (2014) 1.08
Helicobacter pylori infection and the pathogenesis of gastric cancer: a paradigm for host-bacterial interactions. Dig Liver Dis (2008) 1.07